Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CXA-201

National Institute for Health and Care Excellence NICE logo

NICE working to tackle antimicrobial resistance

Two guidelines in development to improve NHS use of antibiotic drugs

- PMLiVE

Cubist launches Zurich base

US antibiotic company expands into Europe

- PMLiVE

Rapid review for Pfizer’s superbug vaccine

FDA to expedite assessment of Clostridium difficile inoculation

- PMLiVE

EMA accepts Cubist antibiotic for review

Follows FDA priority review for ceftolozane/ tazobactam

- PMLiVE

FDA approves antibacterial skin drug Orbactiv

US regulator authorises Medicines Company's treatment for ABSSSI

UK flag

Antimicrobial resistance priority for new UK science minister

Greg Clark announces collaboration led by Medical Research Council

UK flag

UK healthcare professionals urged to say ‘no’ to antibiotics

Royal Colleges issues joint statement to members warning of antimicrobial resistance

UK flag

Pharma industry backs UK antibiotics plan

GSK and ABPI back David Cameron’s call for global action on antimicrobial resistance

- PMLiVE

UK innovation prize to support antibiotic diagnostics

Longitude Prize 2014 offers £10m to develop tool to fight antimicrobial resistance

- PMLiVE

Cubist gets green light from FDA for new antibiotic Sivextro

First drug approved under qualified infectious disease product framework

- PMLiVE

Cubist antibiotic to get priority review in US

FDA will expedite assessment of ceftolozane/ tazobactam

- PMLiVE

Cubist publishes positive data on novel antibiotic

Sivextro offers once-daily alternative for skin infections

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links